Six Growth Opportunities to Prioritize in the Biotics Industry

Picture of Dr. Elizabeth Thundow

Dr. Elizabeth Thundow

Vice President, Food and Nutrition

The global biotic ingredients market was valued at USD 11.61 billion in 2025 and is estimated to reach USD 15.77 billion by 2030, according to Kline’s 2026 biotics intelligence. However, the headline number hides a more important shift.
Value is moving away from undifferentiated ingredients and toward solutions that are clinically validated, designed for a specific application, and increasingly combine more than one biotic type.
In our recent webinar, The Future of Biotics, Dr. Elizabeth Thundow, Smriti Sharma, and Sophie Zhou set out six growth opportunities that suppliers should prioritize next.

1. Next-generation and precision biotics

Source: Kline's Global Biotic Ingredients: Market Outlook 2026

The next wave of value sits in ingredients that are difficult to copy. For example, Akkermansia muciniphila has drawn significant interest as a next-generation probiotic because of its association with gut barrier integrity, metabolic health, and immune function. Moreover, commercial launches are emerging in dietary supplements. Targeted postbiotics and arabinoxylan follow the same logic. 

Human milk oligosaccharides (HMOs) are another good example. 2′-FL accounts for most demand today, while LNnT and other types are gaining commercial traction and regulatory approval, particularly in infant nutrition. 

What it means for suppliers: Value comes from IP and evidence, not volume. Companies that own strains, structures, and clinical data will set the terms. 

2. Beyond digestive health

Source: Kline's Global Biotic Ingredients: Market Outlook 2026

Digestive and gut health remains the anchor of the market, but growth is spreading into wider areas including metabolic health, women’s health, cognition, mood and sleep, and beauty from within. Metabolic health, which spans weight management, satiety, glucose regulation, and cardiometabolic wellness, is one of the fastest-growing benefit areas. In North America, the GLP-1 ecosystem is emerging as a growth engine of its own. 

Women’s health is also gaining momentum. In 2025, Lallemand secured expanded European rights to a women-health probiotic strain, a sign of growing demand for vaginal microbiome solutions in the region. 

What it means for suppliers: Each new benefit area needs its own evidence base and claims strategy, especially in Europe, where health-claim rules are the most stringent. 

3. Pet nutrition

Source: Kline's Global Biotic Ingredients: Market Outlook 2026

Pet nutrition is among the fastest-growing applications for almost every biotic, and pet humanization is driving demand for premium health ingredients, with use expanding across pet supplements and treats. 

Stability is a deciding factor. Keeping live microorganisms viable through processing and storage remains a major technical challenge, which is why spore-forming Bacillus strains and postbiotics are well placed to grow. 

What it means for suppliers: Format stability and species-specific evidence are becoming the price of entry. 

4. Synbiotic platforms

Source: Kline's Global Biotic Ingredients: Market Outlook 2026

Consumer interest in combined probiotic and prebiotic formulations is rising fast, with searches for synbiotics up from about 34,000 to 141,000. It reflects a wider shift in the market, away from probiotic-only thinking and toward ecosystem solutions that span probiotics, prebiotics, and postbiotics. 

What it means for suppliers: Proprietary strains, proven co-stability, and clinical data on the combination are what win. Only a few suppliers can offer the full spectrum, which makes breadth a genuine differentiator. 

5. Partnerships and regional scale-up

Source: Kline's Global Biotic Ingredients: Market Outlook 2026

Brand owners increasingly want science-backed, application-ready solutions rather than standalone ingredients. It favors suppliers that codevelop with formulators from product development through to launch. 

Geographically, scale remains concentrated in NAFTA, but faster growth is shifting toward Latin America and APAC. Investment is following: in April 2026, Novonesis agreed to acquire a fermentation facility in Rayong, Thailand, which can be expanded for HMO production and strengthens Southeast Asian supply. 

What it means for suppliers: Codevelop with formulators and prioritize Latin America and APAC for capacity and commercial investment. 

6. Life-stage nutrition

Source: Kline's Global Biotic Ingredients: Market Outlook 2026

Infant nutrition, healthy aging, medical nutrition, and GLP-1 users all need tailored formulations, robust safety documentation, and often regulatory approval. Specialized nutrition is expected to be one of the faster-growing applications as adult formulas and complete meal-replacement products gain traction. 

What it means for suppliers: Barriers are high, but so is value. The suppliers that clear them face less competition. 

The common thread?

Across all six opportunities, the pattern is the same. Growth is likely to favor suppliers that combine strong scientific validation with diversified biotics capabilities, so that they can build differentiated microbiome solutions rather than compete on volume alone. 

Ready to identify your next growth opportunity?

Kline's Global Biotic Ingredient intelligence sizes demand by type and subtype for pro, pre, and postbiotics across seven applications, seven health-benefit categories, and six regions, with supplier shares for each biotic type and forecasts to 2030. Explore the full analysis by requesting a free demo.
Smart Data. Trusted Expertise. Better Decisions.